Sanofi's Pipeline Candidate Faces Safety Review, Clouding Post-Dupixent Outlook

Sanofi reviews Amlitelimab's benefit-risk after rare adverse events in trials, casting doubt on the $3B potential successor to Dupixent.

The future of Sanofi's key pipeline asset, Amlitelimab, has encountered a hurdle. The French pharmaceutical giant is conducting a thorough review of the drug's benefit-risk profile following the emergence of rare adverse events in clinical trials. This development casts a shadow over a candidate viewed as a potential successor to the company's blockbuster drug, Dupixent.

Clinical Trials and Safety Events

During the clinical investigation of Amlitelimab for atopic dermatitis, two cases of Kaposi’s sarcoma were reported in patients with known risk factors. The first instance was identified in a preliminary analysis of the Phase 2 ATLANTIS trial. Subsequently, a second case was detected in the ongoing, still-blinded Phase 3 ESTUARY study. Sanofi promptly discontinued the Amlitelimab treatment for both individuals, who are now reported to be recovering. To date, a total of 3,778 participants across various indications have received the investigational treatment.

Billions in Potential Revenue at Stake

Market reaction to the news was muted but cautious. Sanofi shares concluded trading on Monday at €81.15. This price level underscores a weaker medium-term performance, with the stock down approximately 17% over a 12-month period.

Analysts are adopting a measured stance in light of the safety signal. UBS has maintained its "Neutral" rating on the company. The bank's analyst, Matthew Weston, currently assesses the probability of the project's commercial success at around 60%. The financial implications are significant, with expert consensus peaking peak sales potential for Amlitelimab at an estimated $3 billion.

The path forward now rests with regulatory authorities, who will scrutinize the available safety data. Should these agencies mandate adjustments to the study protocols, delays in the clinical development program would be inevitable. Such a scenario would postpone the anticipated revenue timeline for this hoped-for future therapy.